Autres langues Nuvation Bio Inc.

Actions

NUVB

US67080N1019

Temps réel estimé Cboe BZX Autres places de cotation 16:56:16 01/05/2024			Varia. 5j.	Varia. 1 janv.
3,085 ^USD	+3,18%		+15,98%	+104,30%

17/04	NUVATION BIO INC. : RBC Capital Markets favorable sur le dossier	ZM
10/04	Nuvation Bio finalise l'acquisition d'AnHeart Therapeutics	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology Annual Meeting	25/04
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Nuvation Bio Closes Acquisition of AnHeart Therapeutics	10/04
Nuvation Bio : Acquisition/Asset Disposal - Form 8-K	10/04
Nuvation Bio Inc. Announces Appointment of Directors	10/04
Nuvation Bio Completes Acquisition of AnHeart Therapeutics	10/04
Nuvation Bio Inc. completed the acquisition of AnHeart Therapeutics Ltd	09/04
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer	28/03
Nuvation Bio Inc. Appoints Colleen Sjogren as Chief Commercial Officer	28/03
North American Morning Briefing : Stocks Set for -2-	28/03
Nuvation Bio Shares Jump After Jefferies Upgrade	27/03
Thinking about buying stock in BigBear.ai, Bitfarms, Paysign, Nuvation Bio, or One Group Hospitality?	27/03
Top Premarket Gainers	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
Nuvation Bio Agrees to Acquire AnHeart Therapeutics in All-Stock Deal -- Shares Fall	25/03
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction	25/03
Nuvation Bio Inc. entered into an Agreement and Plan of Merger to acquire AnHeart Therapeutics Ltd.	25/03
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment	14/03
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors	14/03
Nuvation Bio Inc. Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors	14/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Nuvation Bio Inc.

Actions

NUVB

US67080N1019

Autres langues

Filtres